Our website uses cookies to enable essential features and improve your browsing experience. Additionally, cookies enhance overall website functionality and user experience. By choosing I Accept, you agree to our use of non-essential cookies and other tracking technologies.

You have the ability to manage your settings or withdraw your consent at any time. We are committed to maintaining the privacy and security of your personal information. For detailed information on how we use cookies, including how to manage your privacy and preferences, please visit our cookie policy .
Developmentaid logo
Register
Print
Print
Gates Foundation

Global: To Develop Low-cost Non-hormonal Contraceptives with Fewer Side Effects by Engineering Single-domain Camelid Antibodies (nanobodies) to Block Fusion Between Two Exclusive Sperm and Egg Proteins, Which Is Required for Fertilization

Last update: 1 day ago Last update: Dec 4, 2025

Details

Locations:Canada
Start Date:Nov, 2020
End Date:Nov, 2024
Contract value: USD 1,902,266
Sectors:Health, Research & Innovation
 Health, Research & Innovation
Categories:Grants
Funding Agencies:
Gates Foundation
Date posted:Dec 4, 2025

Associated funding

Associated experts

Description

Purpose: To develop low-cost non-hormonal contraceptives with fewer side effects by engineering single-domain camelid antibodies (nanobodies) to block fusion between two exclusive sperm and egg proteins, which is required for fertilization
Division: Gender Equality
Region served: GLOBAL
Grant topic: Empower Women and Girls
Duration (months): 48
Grantee location: Toronto, Ontario, Canada

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.
Learn more about our membership benefits
Print